Amorphous Transdermal Drug Delivery via Polymeric Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal drug delivery systems face challenges in achieving stable and efficient absorption of therapeutic agents like scopolamine, oxybutynin, naltrexone, testosterone, and estradiol due to the stratum corneum barrier, leading to reduced delivery rates and therapeutic efficacy.
Innovation Solution
A solid dispersion transdermal drug delivery system comprising a therapeutic agent in an amorphous form and a polymeric stabilizer capable of hydrogen bonding, with optimized weight ratios of polymeric stabilizer to therapeutic agent, enhancing stability and absorption through the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemical enhancers are used to overcome the stratum corneum barrier, then drug absorption is improved, but side effects such as skin irritation and formulation incompatibility are introduced
Solution Approach 1:
The patent employs polymeric stabilizers as intermediary substances that form hydrogen bonds with the therapeutic agent to maintain it in an amorphous state, enabling enhanced absorption without introducing harmful chemical enhancers. The polymeric stabilizer acts as a mediator between the drug and the stratum corneum barrier, facilitating transport while avoiding skin irritation.
Solution Approach 2:
The patent changes the physical state parameter of the therapeutic agent from crystalline to amorphous form through the use of polymeric stabilizers. This parameter change enables the drug to penetrate the stratum corneum more effectively while avoiding the need for harmful chemical enhancers, thus improving absorption without increasing skin irritation.
2Productivity
If physical means such as iontophoresis and electroporation are used to overcome the stratum corneum barrier, then drug absorption is improved, but device complexity and ease of operation are reduced
Solution Approach 1:
The patent replaces complex physical delivery mechanisms (iontophoresis, electroporation, sonophoresis) with a chemical approach using polymeric stabilizers that form hydrogen bonds with the therapeutic agent. This substitution maintains enhanced drug absorption while dramatically reducing device complexity and improving ease of operation, as the system requires only simple application without electrical or mechanical equipment.
3Ease of manufacture
If the therapeutic agent is delivered in crystalline form, then manufacturing is simpler, but absorption rate and therapeutic efficacy are reduced
Solution Approach 1:
The patent changes the physical state parameter of the therapeutic agent from crystalline to amorphous form using polymeric stabilizers. Although amorphous forms can be more difficult to manufacture, the patent achieves this transformation through controlled processes that maintain manufacturing feasibility while dramatically improving absorption rate and therapeutic efficacy, as the amorphous form penetrates the stratum corneum more effectively.
4Ease of manufacture
If the polymeric stabilizer weight ratio is not optimized, then manufacturing is easier, but the stability of the therapeutic agent in amorphous form is reduced
Solution Approach 1:
The patent optimizes the weight ratio parameter of the polymeric stabilizer to the specific range of 0.1:1 to 10:1 to achieve the desired balance between manufacturing ease and amorphous form stability. This parameter optimization ensures that the therapeutic agent remains stable in amorphous form while maintaining reasonable manufacturing complexity, as the polymeric stabilizer effectively prevents crystallization within this ratio range.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system maintains at least 95% of the therapeutic agent in an amorphous form for extended periods, significantly increasing skin absorption rates by up to 75% compared to systems without a polymeric stabilizer, ensuring consistent and effective drug delivery.
Implementation Method 1
a polymeric stabilizer capable of hydrogen bonding with the therapeutic agent
Implementation Method 2
absorption of the hydrophilic salts of drugs is especially difficult. Large molecules and extremely hydrophobic drugs also have difficulty being absorbed through the skin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A solid dispersion transdermal drug delivery system comprising a therapeutic agent in a stable amorphous form and a combination polymeric stabilizing and dispersing agent having a hydrogen bond-forming functional group, and a method of manufacturing these systems is provided. The weight ratio of the combination polymeric stabilizing and dispersing agent to the therapeutic agent is also disclosed.